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Cardiovascular disease is the leading worldwide cause of death. Apolipoprotein E (ApoE) is a 34-kDa circulating glycoprotein,
secreted by the liver and macrophages with pleiotropic antiatherogenic functions and hence a candidate to treat hypercholestero-
laemia and atherosclerosis. Here, we describe atheroprotective properties of ApoE, though also potential proatherogenic actions,
and the prevalence of dysfunctional isoforms, outline conventional gene transfer strategies, and then focus on gene correction
therapeutics that can repair defective APOE alleles. In particular, we discuss the possibility and potential beneﬁt of applying in
combination two technical advances to repair aberrant APOE genes: (i) an engineered endonuclease to introduce a double-strand
break (DSB) in exon 4, which contains the common, but dysfunctional, ε2a n dε4 alleles; (ii) an eﬃcient and selectable template
for homologous recombination (HR) repair, namely, an adeno-associated viral (AAV) vector, which harbours wild-type APOE
sequence. This technology is applicable ex vivo, for example to target haematopoietic or induced pluripotent stem cells, and also
for in vivo hepatic gene targeting. It is to be hoped that such emerging technology will eventually translate to patient therapy to
reduce CVD risk.
1.Introduction
Deaths from cardiovascular disease (CVD), which encom-
passes ischaemic heart disease, stroke, and peripheral vas-
cular disease, total about 17 million per year worldwide,
almost one-third of the total [1]. Notably, over 80% of
CVD deaths are in low- and middle-income countries; it is
not a disease conﬁned to developed countries. Atheroscle-
rosis is a progressive inﬂammatory response to complex
interactions between cell types endogenous to the arterial
wall, monocytes, lymphocytes and platelets from blood, and
circulating lipoproteins [2]. Early atherosclerotic lesions are
lipid streaks, characterized by cholesterol-engorged foam
cells within the vascular endothelium. Foam cells originate
from blood monocyte macrophages, which are recruited
into the arterial intima by upregulated adhesion molecules
on activated endothelium. There via unregulated scav-
enger receptors they relentlessly ingest oxidized low-density
lipoprotein (LDL) or triglyceride-depleted (but cholesterol-
containing) remnant lipoprotein particles. Failure to resolve
the inﬂammation eventually leads to smooth muscle cells
inﬁltration, which proliferate within the intima to foster
development of established lesions.
A signiﬁcant risk factor for CVD is increased plasma
LDL. This is susceptible to oxidation and is the main source
of the cholesterol which deposits in arteries during endothe-
liuminjury.Thestatinclassofdrugshelpspreventearlymor-
bidity or death by lowering plasma LDL. However, statins
do not rectify low levels of atheroprotective high-density
lipoproteins (HDLs), which is an important independent
risk factor because of its role in removing excess cholesterol
from arterial walls [3, 4]. Although aggressive high-dose
statins are reported to successfully regress atherosclerotic
plaque with the goal of reducing morbidity and mortality,
the incidence of side eﬀects (liver damage, rhabdomyolysis,
and cancer) increases and the therapeutic value remains
contentious. Similarly, the value of statin treatment in com-
bination with ezetimibe, a cholesterol-absorption inhibitor
which further decreases LDL cholesterol by 15–20%, has
beenquestionedasnosigniﬁcantreductionsinintima-media2 Cardiology Research and Practice
thickness were observed [5]. Alternative strategies to combat
occlusive CVD are still urgently needed for many patients
[3, 4, 6].
These include drugs to raise HDL levels, such as niacin,
inhibitors of cholesteryl ester transfer protein (CETP), and
RVX-208, a small quinazoline-family member which upreg-
ulates ApoAI, the main HDL protein constituent [4–9].
Gene-based therapies are also receiving considerable atten-
tion, including antisense oligonucleotides (ASO) to target
LDL’s structural protein ApoB100 [10]. Gene silencing of
proprotein convertase subtilisin/kexin type 9 (PCSK9) also
lowers LDL indirectly. Secreted PCSK9 binds to the LDL
receptor (LDLR) and accelerates its degradation, and hence
prolonging LDLR activity by PCSK9 inhibition lowers
plasma LDL levels [11, 12]. HDL supplementation agents
are also in clinical use, including infusion of synthetic or
plasma-puriﬁed ApoAI and ApoAI mimetic peptides [13].
Gene addition has also been used to boost plasma ApoAI
and HDL in preclinical studies using adenovirus and adeno-
associated virus (AAV) vectors for delivery [14, 15].
2. The ApoE GeneandProtein
ApolipoproteinE(ApoE)isa34-kDapolymorphicglycopro-
tein largely secreted by liver (∼90%; 40–60μg/mL plasma),
although other tissues particularly macrophages contribute
[16]. The human gene is located on chromosome 19, at
the 5  end of a 50 kb gene cluster comprising ApoCI, an
ApoCI pseudogene, ApoCII, and ApoCIV [3]. Like many
of the soluble apolipoproteins, the ApoE gene has four
exons separated by three introns and is synthesized and
released via the canonical pathway (Figure 1). The primary
translation product is 317 residues containing an N-terminal
18 amino acid (a.a.) signal peptide to direct the growing
ApoE polypeptide to the endoplasmic reticulum. Prior to
secretion, ApoE undergoes O-linked glycosylation in the
Golgi, principally at Thr194 although carbohydrate chains
containing sialic acid are also present on Ser290.
ApoE protein comprises an N-terminal domain (1–191
residues) of four amphipathic α-helices linked to the C-
terminus by a protease-sensitive loop [17]. An arginine- and
lysine-rich segment in helix-4 (residues 134–150; Figure 1)
containstherecognitionsitefortheLDLRandLDLreceptor-
related protein (LRP). ApoE contains two heparin-binding
sites, one within the receptor-binding domain and the other
within the C-terminus (residues 243–272). There are three
common isoforms of ApoE, termed E2, E3, and E4, which
are the products of three alleles (ε2, ε3, and ε4) at a single
gene locus [16]. The ApoE3 (Cys112,A r g 158) is considered
the parent form, while ApoE4 (Arg112,A r g 158)a n dA p o E 2
(Cys112,C y s 158) arise from genetic point mutations and are
variants (Figure 1). There is considerable allelic variation in
diﬀerent populations, but, in Europe, the relative frequencies
are approximately 0.77, 0.15, and 0.08 for ε3, ε4, and ε2[ 18],
giving in order of occurrence E3/3, E4/3, E3/2, E4/4, E4/2,
and E2/2 phenotypes.
The rarest variant ApoE2 is the cause of Type III hyper-
lipoproteinaemia in a small proportion (∼5%) of ε2/2 indi-
viduals, which confers a markedly increased risk of CVD
[19, 20], and the allele is also tentatively linked to intrac-
erebral haemorrhage [21]. Nevertheless, ε2 carriers have
reduced levels of total and LDL cholesterol (see Section 3),
and their risk of coronary heart disease is 20% lower than
people with the common ε3/3 genotype [22], ApoE4 asso-
ciates with incidence of ischaemic stroke and subarachnoid
haemorrhage [21] and produces an adverse lipoprotein
proﬁle, with increased LDL and a slight reduction in HDL
[22]. In 1996, a meta-analysis of 14 studies found that
carriers of the ε4 allele had an increased risk of coronary
heart disease [23], and this was conﬁrmed in a subsequent
meta-analysis of 48 studies involving 15,942 disease cases,
which concluded the risk was 42% higher compared to
ε3/3 carriers [24]. Moreover, the LDL cholesterol level is
30% lower in people with the ε2/2 genotype than with
ε4/4, a reduction comparable to that achieved with statins.
Nevertheless, this supposition of risk for ε4 carriers is
contentious; an updated meta-analysis, which focused on
studies recruiting large numbers of participants to reduce
publication bias, reported only a modest increase of risk
[22].Ontheotherhand,APOE:environmentinteractionson
CVD risk are attracting increased attention [25]; the ε4a l l e l e
potentiates the risk of CVD from physical inactivity and also
from smoking, though mainly in women [26]. In addition,
ε4 carriers have a lower life expectancy, a ﬁnding reﬂecting
their predisposition to neurodegenerative disease as well as
CVD [27, 28].
As detailed in Sections 3 and 4, and independently of
genotype, ApoE has a plethora of actions to inhibit athero-
genesis. Most information has come from studies in vitro or
in mice,and,althoughmanymechanisms areill-understood,
the weight of evidence strongly suggests that ApoE is
atheroprotective. But there is a ﬁnal twist to the tale: plasma
ApoE levels positively correlate with CVD mortality [29],
leaving several unanswered questions concerning human
ApoE biology in health and disease [30].
3.ApoE andLipid-RelatedAtheroprotection
ApoE plays an essential role in the metabolism of dietary
lipids, which enter the circulation as large triglyceride-
rich chylomicron particles. Following lipolysis and uptake
of energy-rich monoglycerides and fatty acids, cholesterol-
containing and potentially atherogenic remnant particles are
left, which depend on ApoE for rapid hepatic clearance via
pathways involving LRP, the LDLR and heparan sulphated
proteoglycans (HSPG) [31]. ApoE4 has marginally greater
receptor-binding capability than ApoE3, but ApoE2 is defec-
tive with only 2% and 40% binding activity to the LDLR
and LRP, respectively. Although the ApoE2 isoform has an
amino acid substitution (Arg158Cys) outside of the 134–150
receptor-binding domain (Figure 1), this has a major disrup-
tive inﬂuence. In ApoE3, a salt bridge is formed between
Arg158 and Asp154. However, this interaction is lost in
ApoE2, and so Asp154 forms a bridge with Arg150, reducing
the positive potential of the binding site to markedly impair
its binding aﬃnity [32].
When ordered E2/2, E2/3, E2/4, E3/3, E3/4, and E4/4,
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Figure 1: Structure of the human APOE gene. The APOE gene has 4 exons, comprising 44, 66, 193, and 860 nucleotides, with over 80% of
the protein coded for by exon 4. Exon 1 contains 5  untranslated sequence, while the translated sequence in exon 2 codes for most of the
18 residue signal peptide. As indicated, exon 4 contains the two common disease-associated SNPs: a T→C point mutation produces ApoE4
(Cys112Arg), while C→T mutation gives ApoE2 (Arg158Cys). The wild-type sequence is ApoE3 (Cys112, Arg158). Also shown in the lower
part of the ﬁgure is the positively charged arginine- and lysine-rich α-helical segment (residues 134–150) which recognizes the LDL receptor.
33]. One explanation is that this reﬂects up-or downregu-
lation of the hepatic LDLR due to changes in cholesterol
delivery by ApoE2- or ApoE4-containing remnant particles,
respectively. Thus, a diminished cholesterol supply by ApoE2
would increase hepatic LDLR numbers to lower plasma
LDL; additionally, reduced competition between ApoE2-
remnants and LDL for binding by the LDLR would result in
accelerated LDL clearance [19]. The higher binding aﬃnity
of ApoE4-containing lipoproteins for the LDLR would have
opposite eﬀects and so raise LDL levels. Nevertheless, the
mechanism is more complex since conversion of VLDL to
LDL is impaired by ApoE2, which reduces the amount of
LDL formed [19].
ApoE also contributes to “reverse cholesterol transport,”
the antiatherogenic HDL-dependent pathway by which
excess cholesterol in peripheral tissues, including arteries,
is brought to the liver for biliary excretion. Such regu-
lation of cellular cholesterol homeostasis, particularly in
macrophages, is vital in preventing foam cell formation and
atherogenesis. Eﬃcient cellular cholesterol eﬄux depends
on ATP-binding cassette transporters (ABCA1 and ABCG1),
but lipid-poor ApoAI- (preβ-1 HDL) and ApoE-containing
particles (γ-LpE) are avid initial cholesterol acceptors. Sig-
niﬁcantly, the plasma γ-LpE fraction from E3/3 subjects
sequestered substantially more cellular cholesterol than the
f r a c t i o n si nE 2 / 2a n dE 4 / 4p l a s m a s[ 34]. Additionally,
ApoE can activate plasma lecithin-cholesterol acyltransferase
(LCAT), CETP, and hepatic lipase (HL), which are all
involved in HDL maturation [16]. As macrophages secrete
ApoE at lesion sites, it is the dominant acceptor in clearing
excess arterial cholesterol. This eﬀect is isoform dependent
with ApoE2/2 human monocyte macrophages secreting
substantially lower amounts of ApoE compared to E3/3 or
E4/4 cells [35], apparently because in macrophages, though
not in hepatocytes, cysteine-rich ApoE2 forms dimers and
multimers which are bound to LRP and retained in the
secretory pathway [36].
These atheroprotective biological functions of ApoE are
corroborated by the hyperlipidaemia and atheroma seen
in ApoE-deﬁcient (ApoE−/−) mice. Normal mice resist
atherosclerosis and even when fed a proatherogenic diet
develop only immature fatty streak lesions [37]. However,
ApoE−/− mice are grossly hypercholesterolaemic on normal
chow and spontaneously develop widespread ﬁbroprolifer-
ative lesions, which evolve into advanced complex plaques
with smooth muscle cell caps and necrotic cores [38].
On the other hand, transgenic animals expressing the
common human ApoE isoforms have revealed more subtle
aspects of ApoE atheroprotection [37]. For example, early
studies in both mice and rabbits showed that overexpression
of ApoE3 was detrimental causing hypertriglyceridaemia.
Excessive production of hepatic ApoE stimulates VLDL
triglyceride synthesis and also inhibits lipoprotein-lipase-
(LPL-) mediated lipolysis, largely by displacing ApoCII an
essential cofactor for LPL from the VLDL surface [19].
However,phenotypicinterpretationsandcomparisonofdata
from diﬀerent groups were sometimes confounded because
the human APOE transgene was inserted into diﬀerent
genomic locations and at varying copy numbers and because
endogenous mouse ApoE protein was also present.
These diﬃculties were mitigated by introduction of gene
replacement strategies to generate mice in which the mouse4 Cardiology Research and Practice
Apoe gene was replaced by a human allele. Nevertheless, such
mice also have limitations: unlike wild-type mice, ApoE3
knock-in animals were susceptible to dietary-induced hyper-
cholesterolaemia and atherosclerosis, apparently because
human ApoE3 has low receptor-binding aﬃnity and is
less eﬃcient at clearing remnant particles [39]. Moreover,
type III hyperlipoproteinaemia in humans homozygous for
the ε2 allele is a recessive condition, whereas a dominant
inheritance is seen in ApoE2 knock-in mice [40]. While
this may also reﬂect binding diﬀerences between human
and mouse receptors, it should be noted that ∼80% of
liver-derived mouse VLDL is ApoB48-containing particles,
and, hence, mice depend much more on ApoE for remnant
clearance than do humans. Interestingly, many of the rare
ApoE variants with amino acid substitutions within the
receptor-binding region do associate with dominant type
III hyperlipoproteinaemia even though most have adequate
receptor-binding activity compared to ApoE2 [19]. Stud-
ies In vitro studies [41], and also in ApoE2 and ApoE
(Arg142Cys) transgenic mice [19] suggest that recessive
ApoE2 retains HSPG binding, allowing remnant clearance
via this alternative pathway [19], whereas the dominant
ApoE variants have negligible binding which translates to an
overall clearance rate lower than that of ApoE2 [31].
4. ApoE and
Lipid- Independent Atheroprotection
It is now recognized that ApoE fulﬁls several biological
functions unrelated to lipid transport and that these make
signiﬁcant contributions to its antiatherogenic activity [16,
42–44]( Figure 2). Most are anti-inﬂammatory in nature
and include the early observation that ApoE restricts T-
cell activation and proliferation [45]. Later, our own studies
showed that cell-derived ApoE inhibited platelet aggregation
and also the expression of vascular cell adhesion molecule
1 (VCAM-1) on endothelial cells, actions mediated by the
common mechanism of ApoE interaction with the cell-
surface receptor, LRP8 (ApoER2) to activate nitric oxide
synthase (NOSIII) and release NO [46, 47]. Additional data
suggest that ApoE stimulates tyrosine phosphorylation of
LRP8 to initiate PI3 kinase signalling and activation of
NOSIII [48]. Induction of smooth muscle cell migration
and proliferation by oxidized LDL or platelet-derived growth
factorarealsosuppressedbyApoE[49],whilesubendothelial
retention of LDL, an early proatherogenic event [50], is
impeded by the presence of ApoE, which additionally
regulates the availability of cytokines and growth factors
within the pericellular proteoglycan matrix [51]. There is
clear evidence that ApoE protects cells and lipoproteins
against lipid oxidation and other oxidative stresses in an
isoform-dependent manner, although ﬁndings can vary
with the experimental system used. In cell-free systems,
metal-induced oxidation is inhibited by ApoE in an allele-
speciﬁc manner (E2>E3>E4), largely because it sequesters
metal ions [52–54]. However, when LDL was incubated
with transfected macrophages secreting equal amounts of
ApoE, the ApoE3 and ApoE4 isoforms provided greater
protection against oxidation than ApoE2 [54]. Transfected
mouseperitoneal macrophageshavealsobeenshowntohave
anti-inﬂammatory properties with ApoE3-expressing cells
secreting lower levels of the proinﬂammatory cytokines IL-
6a n dT N F - α than ApoE2 and ApoE4 cells [55].
Studies in vivo using ApoE−/− mice have also given
importantcluestopossibleatheroprotectiveactionsofApoE.
For example, lipoproteins from ApoE-deﬁcient mice are
more oxidized and prone to oxidation than those from con-
trol mice [56], while clearance of apoptotic cell remnants is
reduced in the absence of ApoE [57]. An anti-inﬂammatory
role for ApoE in dampening inﬂammation induced by
lipopolysaccharide (LPS) or bacteria is postulated based
on the increased susceptibility of ApoE−/− mice compared
to control animals when challenged with such pathogens
[58–60]. By contrast, a speciﬁc proinﬂammatory role for
ApoE was suggested by van den Elzen and colleagues who
showed that ApoE delivers lipid antigens to CD1 endosomal
compartments of antigen-presenting dendritic cells, most
likely via LDLR endocytosis, to stimulate natural killer T-
cells [61]. This activation was lost from ApoE-depleted
human serum and also drastically reduced in ApoE-deﬁcient
mice challenged with an exogenous lipid antigen. The
authors also speculated that ApoE might use this pathway
to deliver self-lipid antigens and exacerbate atherosclerosis,
although such removal of antigenic lipids might also be
atheroprotective. A full description of the cross-talk between
ApoE and cytokines, including modulation of inﬂammatory
and immune responses and isoform dependency, is beyond
the scope of this paper but was recently reviewed by Zhang
and colleagues [44]. Moreover, the (patho)physiological
importance of such lipid-independent actions of ApoE is
highlighted by studies in which low-level expression contin-
ues to provide atheroprotection in ApoE−/− animals, despite
no change in their hyperlipidaemia [42, 62]. Signiﬁcantly,
Raﬀai et al. [63] provided compelling evidence that low
levels of ApoE protein have the capacity to regress preexisting
atherosclerotic lesions, independently of lowering plasma
cholesterol.
5. ApoE Gene-AugmentationTherapeutics
5.1. Early Insights from Protein Therapy and Transgenic Mice.
Twenty years ago plasma-puriﬁed or recombinant ApoE
protein were infused into rabbits with genetic or diet-
induced hypercholesterolaemia. Plasma cholesterol levels
were markedly reduced, while a long-term study halted
atherosclerotic plaque development [64]. This preclinical
evidence endorsed the APOE gene as a candidate for ther-
apeutic manipulation. Similarly, synthetic peptide mimics
of the ApoE binding region (based on a dimeric repeat
of a.a. 141–155) cleared cholesterol-rich lipoproteins in
ApoE−/− mice [65], a strategy which evolved into covalently
coupling ApoE 141–150 residues to an 18 a.a. amphipathic
helicalpeptidecapableofassociatingwithatherogenicApoB-
containing lipoproteins [66]. Thrice weekly intravenous
injection of this dual domain peptide into ApoE−/− mice
for 6 weeks reduced plasma cholesterol and atherosclerotic
lesions in the aortic sinus [67].Cardiology Research and Practice 5
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Figure 2: Proposed atheroprotective functions of ApoE3. The antiatherogenic properties of ApoE3 are divided into those related to its role
in lipid metabolism (shaded area) and those independent (unshaded area).
Use of in vivo ApoE-secreting miniorgans substanti-
ates these antiatherogenic actions of ApoE peptides and
puriﬁed protein. Recombinant ApoE-expressing endothelial
cells embedded in Matrigel were injected intradermally
into ApoE−/− mice which, 3 months later, had 50% less
plasma cholesterol and reduced atherosclerotic plaque [68].
Similarly, implantation of alginate-encapsulated engineered
cells into the peritoneum of ApoE−/− mice secreted suﬃcient
ApoE to lower plasma cholesterol and increase atheropro-
tective HDL [69]. Transgenic mice overexpressing ApoE
provide additional evidence for ApoE atheroprotection, as
these animals are protected from diet-induced or diabetic
hyperlipidemia [70, 71]. Moreover, macrophage-restricted
expression of ApoE in transgenic mice [72], or in ApoE−/−
mice following transplantation of wild-type bone marrow
[73, 74], inhibits atherogenesis.
5.2. ApoE Gene Transfer Studies. Gene transfer of ApoE was
ﬁrst reported 16 years ago using recombinant adenovirus
(rAd) vectors, which deliver foreign DNA into mammalian
liver with near-100% eﬃciency. High levels of plasma ApoE
were obtained following intravenous injection of rAd.ApoE3
into ApoE−/− mice, which reduced plasma cholesterol
and slowed aortic atherogenesis [75]. Unfortunately, the
therapeutic eﬀect was transient, as these 1st generation
vectors triggered a strong T-cell immunological response. By
contrast,2ndgenerationvectorsgavesustainedhumanApoE
expression and largely normalized the lipoprotein proﬁle in
ApoE−/− mice throughout the 6 week study [76]. Moreover,
in hyperlipidaemic LDLR null mice, hepatic expression of
human ApoE3 induced regression of preexisting atheroscle-
rotic lesions without altering plasma lipoprotein levels
[77], implying lipid-independent atheroprotective actions
(Figure 2). The potential to regress advanced atheroma in
older animals was also noted [78], while the low toxicity
and low immunogenicity of helper-dependent rAd vectors
allowed high stable expression of ApoE and lifelong athero-
protection in ApoE−/− mice [79].
An alternative viral vector to rAd is adeno-associated
virus (AAV), which contains a linear single-stranded DNA
genome and is now at the forefront of clinical gene therapy
trials. Early studies used vectors derived from the common
serotype 2, which transduced cells very eﬃciently in vitro,
but unfortunately were largely ineﬀective in vivo. However,
the ﬁeld was boosted by the isolation of over 10 new
serotypes, which led to development of new pseudotyped
rAAV vectors that is, capsids of alternative AAV serotypes
harbouring the recombinant AAV serotype 2 genome. These
had strikingly improved performances in vivo and diﬀerent
tissue tropisms to AAV2/2; for example, rAAV2/8 transduced
liver with near-100% eﬃciency [80–82], while rAAV2/1 [83],
rAAV2/6 [84] or rAAV2/7 [85]w e r ee ﬀective for skeletal
muscle transduction.
This increased serotype eﬃciency was shown by intra-
venous(liver-directed)injectionofahumanApoE3rAAV2/8
vector into ApoE−/− mice; normal human levels (50-
80μg/mL) of plasma ApoE were produced [58]. It is pro-
posed that, unlike serotype 2, these diﬀerent AAV serotypes
uncoat rapidly to facilitate annealing of the single-stranded
plus and minus rAAV genomes into stable, transcriptionally6 Cardiology Research and Practice
active double-stranded DNA molecules [86]. Similarly, the
recent introduction of self-complementary rAAV (scAAV)
vectors, which circumvent the need for annealing rAAV
vector genomes, allows a rapid and higher level of transgene
expression [87, 88]. For example, expression of ApoE3 from
scAAV2/8 using the hepatocyte-speciﬁc promoter (LP1)
normalized cholesterol levels in male ApoE−/− mice and
retarded development of aortic atherosclerosis by 58% [89].
Skeletal muscle, an accessible, stable, and well-vascu-
larized tissue, has also been used for gene transfer of
ApoE. Although muscle does not normally secrete ApoE,
nonhepatic, nonmacrophage-derived ApoE is known to be
atheroprotective [62, 90]. Indeed, intramuscular injection
of a plasmid DNA vector expressing human ApoE3 into
ApoE−/− mice gave modest but sustained lowering of plasma
cholesterol [91], while another study reported reduced
xanthoma and atherosclerotic plaque formation [92]. The
high purity and low immunogenicity of plasmids, which
are expressed episomally making insertional mutagenesis
improbable, make them attractive delivery vehicles. Expres-
sion can be further increased by electropulsing the injection
sites(s) [93]. Additionally, we have injected AAV2/7, AAV2/8,
and AAV2/9 vectors expressing human ApoE3 into the
tibialis anterior muscles of ApoE−/− mice. The ﬁrst two
vectors were the most eﬀective, producing up to 2μg
ApoE3/mL plasma, and, at 13 weeks, the mice had 50% less
plaque lipid in brachiocephalic arteries than AAV2/9-treated
animals [94].
6.Oligonucleotide-Mediated GeneEditing
of the Human APOE GeneinCulturedCells
6.1. Background. Gene editing, as described herein, uses
short synthetic oligonucleotides to manipulate genomic
DNA and introduce small, site-speciﬁc changes, typically
1–3 nucleotides, into a selected gene of a living cell. It
has potential, therefore, for introducing speciﬁc mutations,
gain or loss of function, into cell lines or mouse strains,
and for studying single-nucleotide polymorphisms (SNPs).
Below and in Section 7, we describe some of the strategies
used to achieve genotypic modiﬁcations. However, it is
important to note that, unlike gene transfer technologies,
the change is permanent; moreover, existing gene enhancers
and promoters, and cell-speciﬁc control and context, are
retained. These advantages underpin its ultimate goal: the
cureofhereditarydiseasescausedbygeneticpointmutations
or small deletions/insertions. First, we explain why synthetic
oligonucleotides, which are relatively inexpensive and oﬀer
ﬂexible design and chemistry, remain of value for generating
new isogenic cell lines, for example, to investigate diﬀerential
eﬀects of ApoE isoforms on cellular metabolism. Second in
Section 7.wedescribetherapidprogressbeingmadetowards
therapeutic applications, for example, the ex vivo or in situ
repair of genetic point mutations.
6.2. Gene Editing: Early Use of RNA-DNA Oligonucleotides.
Conceptually,thistechnologyisfoundedontheindependent
observations of Smithies and Capecchi in the 1980s that
homologousrecombination(HR)betweenalargeexogenous
DNA segment and its target sequence in a mammalian
genome can mediate genomic modiﬁcation or repair [95,
96]; it also draws on the application of short synthetic
oligonucleotides to repair defective alleles in yeast [97].
The use of hybrid RNA-DNA oligonucleotides (RDOs or
chimeraplasts) to introduce site-speciﬁc changes of 1–3
nucleotides into mammalian genomes was reported 15 years
ago by the Kmiec group [98]. They constructed RDOs
to form a double-stranded, hairpin-capped oligonucleotide
incorporating a short region of correcting DNA bounded
by long stretches of protected 2 -O-methyl RNA. The strong
RNA-DNA base pairing was considered to promote strand
invasion and annealing to the target (e.g., a genetic point
mutation) genomic locus. This high-aﬃnity hybridisation
involves both strands of the gene and creates the mismatch
at the point mutation, leading to recognition and correction
by one or more of the mammalian gene repair pathways. The
early studies of Kmiec and colleagues in repairing the sickle
cell mutation in a lymphoblastoid cell line [99] and in target-
ing primary CD34+ cells [100] generated much excitement,
but also notable controversy as the reported conversion
eﬃciencies of up to 50% were considered implausible [101].
However, these criticisms were deﬂected by corroboration
from others, including targeting human hepatocyte cells
[102, 103] and, in landmark studies, in vivo targeting of the
rat factor IX gene [104] and correction of the UGT1A1 gene
mutation in the hyperbilirubinaemic Gunn rat [105].
Based on these successes, our laboratory pioneered the
technique in cardiovascular disease, including conversion
of dysfunctional ApoE2 [106]a n dA p o E 4[ 107]t oA p o E 3
using a standard 68-mer RDO for targeting. However, the
practicality of this emerging methodology was questioned
whenseveralgroups,ourownincluded,begantoreportpoor
reproducibility and unstable conversions [108, 109]. One
adverse factor was variable quality of the long and complex
RDO molecules, which meant higher doses of reagents and
delivery vehicles to eﬀect repair; in turn, these would amplify
cytotoxic and proapoptotic actions or induce cell cycle arrest
[107, 109]. The problematic nature of these 1st generation
reagents was mitigated, however, by ﬁndings from the Kmiec
group that the all-DNA strand of the RDO initializes the
genomic repair [110] and that a single-stranded all-DNA
oligonucleotide (ssODN) could outperform the RDO if
protected from nuclease degradation by chemical modiﬁca-
tion of bases [111]. As described in Section 6.3, these data
prompted us to switch to short (27-mer) ssODNs, which are
purer and give increased reproducibility.
6.3. Gene Editing: Use of Single-Stranded All-DNA Oligonu-
cleotides (ssODNs). The targeting ssODNs are homologous
to the genomic sequence except for the desired change—
a mismatch to introduce or correct a point mutation, or
short insertion/deletion. As single-stranded DNA is rapidly
degraded within cells, ssODNs are generally protected with
modiﬁed nuclease-resistant bases, most commonly three
phosphorothioate (PTO) bonds at their 5  and 3  ends.
Molecular details of targeted gene alteration remain poorly
delineated but include elements of nucleotide and base exci-Cardiology Research and Practice 7
sion repair systems and also some degree of HR involvement
[112, 113], while at leastpart of the correcting DNA oligonu-
cleotide is physically incorporated into the genomic target
site [114]. Given the diﬃculties and controversies associated
with RDO-directed repairs, we decided to optimize our
methodology in recombinant mammalian cells expressing
a sensitive reporter gene, green ﬂuorescent protein (GFP)
which was rendered nonﬂuorescent by introduction of a
point mutation. This allowed analysis at the single cell level
andtheharvestingofcorrected(green)cellsforfurtherstudy.
We provided stringent evidence to validate the technology
and to establish unequivocally that ssODN-mediated gene
alteration is a real and reproducible phenomenon [115].
Although 5 -3 -PTO protection gave 10-fold greater cor-
rection eﬃciencies than unmodiﬁed ssODN (about 2%
versus 0.2% of targeted cells were green), we conﬁrmed
the observation of others [111] that only a low percentage
of these green cells was actively replicating [116]. Cell
cycle analysis 16h posttransfection revealed that the ssODN
with PTO end protection resulted in DNA damage with
accumulation of cells in the G2 phase, whereas treatment
with unmodiﬁed ssODN was markedly less toxic. However,
by varying the type or position of protecting groups, we
discovered that internal protection of the ssODN with
four PTO residues at the targeting site maintained eﬃcient
gene correction and, compared to 5 -3 -PTO protection,
substantially reduced cell cycle arrest to enable cell growth
and proliferation (Figure 3)[ 116].
We are currently evaluating this novel ssODN design
in targeting the endogenous APOE3 gene in human THP1
monocyte macrophages and human HepG2 hepatoblastoma
cells (both ε3/ε3) to generate cells with the ApoE4 phe-
notype. We have devised an aﬃnity-capture matrix to dis-
tinguish successfully targeted ApoE4-secreting cells (<1%)
from noncorrected ApoE3 cells. This uses low permeability
carboxymethyl-cellulosemediapreloadedwithacommercial
ApoE4-speciﬁc monoclonal antibody for detection and gives
sensitive and reproducible ﬁndings. Secreted ApoE was
readily trapped on the surface of individual cells, enhancing
staining eﬃciency and decreasing assay time. Enriched
corrected populations of ApoE4-secreting cells have been
detected, although isolation and expansion of corrected
clones is proving diﬃcult. Should a successful clone be
identiﬁed and characterized, then it will undergo a 2nd
targeting to generate the ApoE4/4 phenotype.
These experiments are notable for two reasons. First,
they will provide conclusive proof that ssODN-directed gene
editing can generate new cell lines, here, with E3/E4 and
E4/4 phenotypes, although a similar strategy can generate
the other common phenotypes (E2/E3, E2/2, and E2/4) if an
ApoE2-speciﬁcantibodyisused[117].Second,becausethese
isogeniccellscanbeusedtoinvestigateisoformdiﬀerencesin
macrophage(andhepatocyte)ApoEtraﬃckingandsecretion
[35, 36], to monitor diﬀerential cellular responses to oxidant
stress or to cholesterol loading and to investigate variation
in structure and composition of secreted ApoE lipoprotein
particles [48].
7. Therapeutic In Situ Correction of
DefectiveAPOE Genes
7.1. Rationale for ApoE Gene Repair. Most of the in vivo
studies described in Sections 2–4 have used ApoE null mice.
These gave important insights into ApoE functions and
allowed ready evaluation of protein and gene therapeutics.
However, as genetic deﬁciency of ApoE and absent plasma
ApoE is extremely rare in humans, the value of such a
preclinical model is questionable. It is noteworthy, therefore,
that augmentation of plasma ApoE via transgenic expression
or gene transfer has conﬁrmed its atheroprotective function
in LDLR deﬁcient mice and in diabetic or fat-fed mice, all
of which have normal levels of plasma ApoE. Nevertheless,
animal studies also indicate caution in augmenting ApoE3
expression using gene transfer technologies; overexpression
in mice and rabbits causes hypertriglyceridaemia [19].
An alternative and attractive approach, albeit a distant
therapeutic goal, is to alleviate dyslipoproteinaemia and
reduce CVD risk by in situ correction of a deleterious
APOE gene using targeted gene editing. Is this feasible?
One possibility, founded on the multiple atheroprotective
actions of macrophage-secreted ApoE3, is to cure type III
hyperlipoproteinaemia by transplantation of haematopoietic
stem cells (HSCs), following ex vivo repair of the aberrant
APOE gene. As the condition is recessive, conversion of
one ε2a l l e l et oε3 should provide eﬀective treatment.
Moreover, the current impetus in bringing stem cell tech-
nologies to the clinic, particularly induced pluripotent stem
cells (iPSCs), suggests additional possibilities for ex vivo
manipulations and cell-based therapies [118]. These include
eﬃcient diﬀerentiation to functional hepatocyte-like cells
[119–121], which would allow a repaired APOE gene to
be expressed from cells engrafted into liver. Finally, there
is also the exciting prospect of direct in vivo hepatic gene
targetingforinsitucorrectionofgeneticdisease[122].These
sophisticated therapies to repair defective genes in the future
will rely on more advanced technologies than simple nuclear
delivery of ssODNs and these are discussed in the remaining
sections of this paper.
7.2. DNA Repair Templates. The ssODNs we have used for
targeting of the APOE gene have several advantages: high
purity and simple production, including variable chemistry,
easy delivery, and high ﬁdelity with no oﬀ-target eﬀects.
Although ssODNs and other constructs such as triple
helix forming oligonucleotides and small homologous DNA
fragments [113] can act as DNA repair templates, the most
eﬀective is adeno-associated virus (AAV), which carries a
linear single-stranded DNA genome. Though technically
challenging to produce, these viral vectors can genetically
target embryonic stem cells (ESCs), HSCs, or iPSCs achiev-
ing correction eﬃciencies of 0.07–1% [113, 123–125]. The
mechanism, as illustrated in Figure 5, for targeting and gene
repair of defective APOE2 is via homologous recombination
(HR), as silencing essential components of the potentially
competitive pathway, nonhomologous end joining (NHEJ)
has no eﬀect on conversion frequencies [126]. Note too that
the targeting vector can harbour a selectable marker, such8 Cardiology Research and Practice
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Figure 3: Eﬀects of nuclease-protected ssODNs on targeted gene repair. Recombinant cells expressing mutated (nonﬂuorescent) green
ﬂuorescent protein (GFP) were targeted with two ssODNs, one with three phosphorothioate (PTO) residues at each end (a) and the other
with four internal PTOs at the central correcting segment (b). Posttargeting, the green cells were counted by ﬂow cytometry (left panels),
stained for cell cycle analysis (central panels) and cultured to observe cell growth (right panels). The PTO end-protected ssODN gave a
much higher rate of gene correction, as measured by the number of green cells (boxes in left panels). However, this resulted in DNA damage
and accrual of cells in the G2 phase, whereas the GFP+ve cells obtained after internally protected ssODN targeting had a markedly greater
proportioninG1(centralpanel).Signiﬁcantly,onlytheoccasionaldividedpairofgreencellswasnotedinculturestreatedwithend-protected
ssODN, whereas actively replicating green cells were evident when the internally protected ssODN was used (right panels).
Chromosomal DNA
C158
Homologous R158
AAV Repair
R158
template
recombination
APOE2a l l e l e
APOE3a l l e l e
Figure 4: Conversion of the mutant APOE2 allele to wild-type APOE3 using an AAV-based DNA repair sequence. The single-stranded
adeno-associated virus genome, which contains Exon 4 of APOE3 and its ﬂanking regions within its ITRs (inverted terminal repeats), is an
eﬃcient recombination template. As indicated, the mechanism is via a homologous recombination (HR) pathway.Cardiology Research and Practice 9
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Figure 5: Double-strand breaks (DSBs) stimulate homologous recombination (HR) repair. HR facilitates exchange of DNA sequence
between donor and acceptor molecules, provided they share a certain amount of sequence similarity. Donor DNA molecules are designed to
contain a central “repair” sequence, ﬂanked by “homology” arms, whose sequence is identical to that of the acceptor (e.g., genomic) DNA.
Through HR, the repair sequence replaces the entire sequence lying between the crossover points (marked with an X) on the acceptor. Gene
targeting exploits HR in this way to make genetic changes to a cell’s DNA. Importantly, introduction of a DSB into the acceptor sequence,
whichcanbeachievedbyaddinganengineerednucleasewithlocus-speciﬁccleavage(seeFigure 6),markedlyincreasesgenerepaireﬃciency.
as puromycin N-acetyl-transferase, between the homology
arms, which if ﬂanked by two LoxP sites can be excised
from the genome of repaired cells by Cre-recombinase. More
recently, helper-dependent adenoviral vectors (HDAdVs)
have also been used for eﬃcient and accurate gene targeting
of human ESCs and iPSCs [127, 128]. These vectors are
capable of correcting large genomic regions (∼35kb) and
are unaﬀected if the target locus is transcriptionally inactive
[129].
7.3. Double-Strand Breaks (DSBs) Markedly Stimulate HR
Gene Repair. Although HR-directed gene repair is accurate
and versatile, as illustrated in Figures 4 and 5,i to c c u r s
with a very low frequency in mammalian cells (∼10−6) using
conventional linear targeting plasmids as templates [130].
However, HR is one way in which cells repair double-strand
DNA breaks, for example, by using the sister chromatid
as a template, and this phenomenon has been exploited
to increase HR gene-targeting events over 1000-fold. Initial
studies inserted the rare cutting site for the meganuclease,
I-SceI, within a reporter target gene and then cotransfected
cells with the endonuclease and a repair DNA template
[131, 132]. Nevertheless, such a system has little practical
value; it requires prior engineering of the target gene and
cannot be used for endogenous genes.
Recent work in engineering artiﬁcial endonucleases now
circumvents this bottleneck by creating chimeric nucleases
with the potential to cleave DNA at virtually any desired
sequence. The most studied are the zinc ﬁnger nucleases
(ZFNs), which comprise a DNA-binding domain (assembled
as 3–5 ﬁnger modules, each recognizing 3 consecutive bases)
joined to the nonspeciﬁc DNA cleavage enzyme, FokI.I n
principle, customized ZFNs which function in pairs as
FokI cleavage requires dimerization can be created with
predetermined sequence speciﬁcity to introduce a DSB at a
precise genomic locus (Figure 6). Within the last few years,
an impressive number of ZFN gene targeting successes has
been reported, including in vitro corrections of 18–30%,
the generation of gene-knockout rats, and manipulation
of human embryonic or induced pluripotent stem cells
[113, 133–136]. One concern of ZFNs is genotoxicity due
to oﬀ-target cleavages that may disrupt normal genes [137],
although improved designs and screening procedures are
helping to reduce this possibility [138, 139]. As second
problem is that ZFNs can recleave a repaired site, although
this can be minimized by introducing a few silent mutations
into the donor DNA template as this will impair subsequent
ZFN binding [140].
Transcription activator-like eﬀector nucleases (TALENs)
are another group of chimeric nucleases, which have a
diﬀerent class of DNA-binding domains coupled to FokI.
TAL eﬀector proteins contain highly modular DNA-binding
domains, with a very simple code between their amino acids
and target DNA bases [141, 142]. This allows the ready
assembly of a series of individual modules to bind a unique
DNA sequence and to activate FokI dimerization and cleav-
age. Although reports of TALEN-mediated gene targeting of
mammalian cells are still limited, this simple and eﬀective
technology may soon supersede ZFNs; indeed, in the ﬁrst
direct comparison, TALENs had greater speciﬁcity and less
cytotoxicity than ZFNs [143].
Finally, an alternative to engineered chimeric nucleases
are the homing endonucleases, which induce DSBs with
exceptional speciﬁcity. These are natural enzymes with large10 Cardiology Research and Practice
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Figure 6: Basic structure and design of a zinc ﬁnger nuclease (ZFN). ZFNs are created by joining a DNA-binding region to the catalytic
domain of the nonspeciﬁc Fok1 endonuclease. Zinc ﬁngers are a protein motif capable of DNA binding, whose sequence speciﬁcity can be
predetermined. Each zinc ﬁnger, illustrated by an individual circle, recognizes 3-4 nucleotides, and, by assembling three or four suitable zinc
ﬁnger motifs, a sequence-speciﬁc DNA-binding domain can be created. Fok1 nuclease activity requires dimerization, and so the customized
ZFNs function in pairs. As shown, the zinc ﬁnger-binding domain brings two Fok1 units together in the right orientation over the target
sequence; this induces Fok1 dimerization and target sequence cleavage.
asymmetric recognition sequences (12–40bp) that form
ﬁve families based on sequence and structure homology
[144, 145]. “Mix and match” engineering, aided by com-
putation, allows production and validation of dozens of
customized meganucleases, most based on the laglidadg
family sequence motif. In turn, prospective DSB sites can
be predicted across the entire human genome. This suggests
that it will be possible to identify a unique >14-bp sequence
within exon 4 of the APOE gene that can be cleaved by a
homing meganuclease.
7.4. ZFN-ssODN Combinations. To date, the most common
template for DSB repair-dependent gene targeting has been a
circular or linear plasmid, although advantages of using AAV
as the exogenous DNA donor substrate are now emerging
[146–148]. However, exciting new work establishes that
the ZFN-ssODN combination oﬀers ﬂexible and eﬃcient
genome editing. Chen and colleagues [149] used ZFNs that
cut within the ssODN homology area and reported editing
frequencies between 1 and 30% depending on the cell type
and whether the targets were single nucleotide substitutions
or small to large deletions. Importantly, the ssODN appeared
am o r ee ﬃcient and faithful recombination partner than
traditional double-stranded DNA constructs, most likely
because ssODN does not participate in NHEJ and hence
will not insert into nonspeciﬁc cleavage sites. Indeed, the
duo of ZFN-ssODN has already been used to successfully
edit human iPS cells [150]. Given that ssODNs are easier
and cheaper to produce in bulk, have high purity and safety
proﬁles,andrelativelyeasytodeliver,itseemslikelythattheir
use will continue to expand.
8. Concluding Remarks
The technology to repair inborn genetic mutations in cells,
including haematopoietic stem cells and induced pluripotent
stem cells, has developed rapidly during the last few years.
In situ correction of the dysfunctional ε2a n dε4a l l e l e s
to alleviate hyperlipidaemia and counteract the progression
of atherosclerosis is now a preclinical reality. It is also
translatable to patients. The combination of a selectable
AAV-based DNA template for eﬃcient HR repair, which is
further stimulated by the safe and precise introduction of
a DSB at the target genomic locus, provides the necessary
technological tools [146, 147, 151]. Indeed, genome editing
using engineered endonucleases was recently announced as
Nature’s Method of the Year for 2011 [152].
Repairing the defective APOE2 gene in bone mar-
row (lineage-negative) stem cells from patients with
type III hyperlipoproteinaemia, followed by nonmyeloab-
lative (reduced-intensity) transplantation, will provide
macrophage-secreted antiatherogenic ApoE3 at lesions sites
and halt atherosclerotic plaque progression. This therapeutic
approach can be critically evaluated in a preclinical model,Cardiology Research and Practice 11
the human ApoE2 knock-in mouse. Moreover, the prospect
of direct in vivo hepatic gene targeting for in situ correction
of dysfunctional ε2 alleles is no longer a distant dream.
Codelivery via hepatotropic AAV8 vectors of a chimeric
nuclease and donor DNA template to the livers of mice with
blood factor IX deﬁciency restored haemostasis [122].
Is there a case for also converting the ε4a l l e l et oε3
to reduce CVD risk when, as outlined in Section 2, the
increase may only be marginal even for the ε4/ε4 carriers?
Undoubtedly,thecasecanbeargued:withinthisgroup,there
will certainly be individuals who would beneﬁt, perhaps
because their LDL is in the top decile of ε4/ε4 carriers or
because they have other risk factors. The future prospect of
editing the gene in macrophages and/or liver will also allow
a more ﬂexible therapeutic approach. Given that the ε2a l l e l e
is associated with low LDL and reduced CVD, we can also
speculate that a better therapeutic option is to convert cells
from ε4/ε4 to the ε4/ε2 genotype, rather than ε4/ε3. What is
clear, however, is that ApoE, which in 1973 was identiﬁed in
humanVLDL[153],hasmultiplerolesinhumancellbiology
and disease and that, despite impressive understanding of
these functions over the last two decades, we still have much
more to discover. In time, it is to be hoped that such insights,
coupled with the emerging technology of ex vivo or in situ
editing of the human APOE gene, will eventually translate to
patient therapy to reduce CVD risk.
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